Effect of an intensive chemotherapy followed by mediastinal irradiation on pulmonary and cardiac function in advanced Hodgkin's disease

Fabrizio Villani, A. Fede Catania, A. Laffranchi, L. Maffioli, S. Viviani, V. Bonfante

Research output: Contribution to journalArticle

Abstract

Mediastinal irradiation combined with chemotherapy in patients with Hodgkin's disease nave been associated with cardiopulmonary toxic effects that can last over the years. In this study we monitored pulmonary and cardiac function in 39 patients affected by advanced Hodgkin's disease (stage II B-III and IV) with mediastinal involvement and submitted to an intensive chemotherapy regimen (epirubicin, vincristine, ciclophosphamide, and etoposide) followed by involved field irradiation. Pulmonary function was verified with chest x-ray, spirometric parameters, arterial blood gas analysis, single breath CO transfer factor (DLCO), and its components Dm and Vc. Cardiac function was verified with electrocardiogram (EKG) and left ventricular ejection fraction (LVEF) by means of radionuclide angiocardiography. The median follow-up was 40 months. Spirometric parameters did no show modifications at the end of treatment, on the contrary they improved during the follow-up. Chest x-ray showed radiographic parenchimal damage in 51% of patients. DLCO remained constantly decreased. sEKG did not show significant modification, whereas LVEF significantly decreased at the end of treatment and remained persistently decreased during follow-up. None of the patients with reduction of DLCO or LVEF showed clinical symptoms of heart and pulmonary dysfunctions. One patient, 49 years old, suffered from myocardial infarction 25 months after the completion of radio-chemotherapy. These data indicate that this combined regimen can induce persistent pulmonary and cardiac damages at subclinical level.

Original languageEnglish
Pages (from-to)185-192
Number of pages8
JournalCancer Investigation
Volume21
Issue number2
DOIs
Publication statusPublished - 2003

Fingerprint

Hodgkin Disease
Drug Therapy
Lung
Stroke Volume
Electrocardiography
Thorax
X-Rays
Angiocardiography
Transfer Factor
Epirubicin
Blood Gas Analysis
Poisons
Vincristine
Etoposide
Carbon Monoxide
Radio
Radioisotopes
Myocardial Infarction
Therapeutics

Keywords

  • Cardiac function
  • Chemotherapy
  • Hodgkin's disease
  • Pulmonary function
  • Radiotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Effect of an intensive chemotherapy followed by mediastinal irradiation on pulmonary and cardiac function in advanced Hodgkin's disease. / Villani, Fabrizio; Catania, A. Fede; Laffranchi, A.; Maffioli, L.; Viviani, S.; Bonfante, V.

In: Cancer Investigation, Vol. 21, No. 2, 2003, p. 185-192.

Research output: Contribution to journalArticle

@article{2c45d24672da4a5ba08b6d760d8b7101,
title = "Effect of an intensive chemotherapy followed by mediastinal irradiation on pulmonary and cardiac function in advanced Hodgkin's disease",
abstract = "Mediastinal irradiation combined with chemotherapy in patients with Hodgkin's disease nave been associated with cardiopulmonary toxic effects that can last over the years. In this study we monitored pulmonary and cardiac function in 39 patients affected by advanced Hodgkin's disease (stage II B-III and IV) with mediastinal involvement and submitted to an intensive chemotherapy regimen (epirubicin, vincristine, ciclophosphamide, and etoposide) followed by involved field irradiation. Pulmonary function was verified with chest x-ray, spirometric parameters, arterial blood gas analysis, single breath CO transfer factor (DLCO), and its components Dm and Vc. Cardiac function was verified with electrocardiogram (EKG) and left ventricular ejection fraction (LVEF) by means of radionuclide angiocardiography. The median follow-up was 40 months. Spirometric parameters did no show modifications at the end of treatment, on the contrary they improved during the follow-up. Chest x-ray showed radiographic parenchimal damage in 51{\%} of patients. DLCO remained constantly decreased. sEKG did not show significant modification, whereas LVEF significantly decreased at the end of treatment and remained persistently decreased during follow-up. None of the patients with reduction of DLCO or LVEF showed clinical symptoms of heart and pulmonary dysfunctions. One patient, 49 years old, suffered from myocardial infarction 25 months after the completion of radio-chemotherapy. These data indicate that this combined regimen can induce persistent pulmonary and cardiac damages at subclinical level.",
keywords = "Cardiac function, Chemotherapy, Hodgkin's disease, Pulmonary function, Radiotherapy",
author = "Fabrizio Villani and Catania, {A. Fede} and A. Laffranchi and L. Maffioli and S. Viviani and V. Bonfante",
year = "2003",
doi = "10.1081/CNV-120016414",
language = "English",
volume = "21",
pages = "185--192",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Effect of an intensive chemotherapy followed by mediastinal irradiation on pulmonary and cardiac function in advanced Hodgkin's disease

AU - Villani, Fabrizio

AU - Catania, A. Fede

AU - Laffranchi, A.

AU - Maffioli, L.

AU - Viviani, S.

AU - Bonfante, V.

PY - 2003

Y1 - 2003

N2 - Mediastinal irradiation combined with chemotherapy in patients with Hodgkin's disease nave been associated with cardiopulmonary toxic effects that can last over the years. In this study we monitored pulmonary and cardiac function in 39 patients affected by advanced Hodgkin's disease (stage II B-III and IV) with mediastinal involvement and submitted to an intensive chemotherapy regimen (epirubicin, vincristine, ciclophosphamide, and etoposide) followed by involved field irradiation. Pulmonary function was verified with chest x-ray, spirometric parameters, arterial blood gas analysis, single breath CO transfer factor (DLCO), and its components Dm and Vc. Cardiac function was verified with electrocardiogram (EKG) and left ventricular ejection fraction (LVEF) by means of radionuclide angiocardiography. The median follow-up was 40 months. Spirometric parameters did no show modifications at the end of treatment, on the contrary they improved during the follow-up. Chest x-ray showed radiographic parenchimal damage in 51% of patients. DLCO remained constantly decreased. sEKG did not show significant modification, whereas LVEF significantly decreased at the end of treatment and remained persistently decreased during follow-up. None of the patients with reduction of DLCO or LVEF showed clinical symptoms of heart and pulmonary dysfunctions. One patient, 49 years old, suffered from myocardial infarction 25 months after the completion of radio-chemotherapy. These data indicate that this combined regimen can induce persistent pulmonary and cardiac damages at subclinical level.

AB - Mediastinal irradiation combined with chemotherapy in patients with Hodgkin's disease nave been associated with cardiopulmonary toxic effects that can last over the years. In this study we monitored pulmonary and cardiac function in 39 patients affected by advanced Hodgkin's disease (stage II B-III and IV) with mediastinal involvement and submitted to an intensive chemotherapy regimen (epirubicin, vincristine, ciclophosphamide, and etoposide) followed by involved field irradiation. Pulmonary function was verified with chest x-ray, spirometric parameters, arterial blood gas analysis, single breath CO transfer factor (DLCO), and its components Dm and Vc. Cardiac function was verified with electrocardiogram (EKG) and left ventricular ejection fraction (LVEF) by means of radionuclide angiocardiography. The median follow-up was 40 months. Spirometric parameters did no show modifications at the end of treatment, on the contrary they improved during the follow-up. Chest x-ray showed radiographic parenchimal damage in 51% of patients. DLCO remained constantly decreased. sEKG did not show significant modification, whereas LVEF significantly decreased at the end of treatment and remained persistently decreased during follow-up. None of the patients with reduction of DLCO or LVEF showed clinical symptoms of heart and pulmonary dysfunctions. One patient, 49 years old, suffered from myocardial infarction 25 months after the completion of radio-chemotherapy. These data indicate that this combined regimen can induce persistent pulmonary and cardiac damages at subclinical level.

KW - Cardiac function

KW - Chemotherapy

KW - Hodgkin's disease

KW - Pulmonary function

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=0038755144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038755144&partnerID=8YFLogxK

U2 - 10.1081/CNV-120016414

DO - 10.1081/CNV-120016414

M3 - Article

C2 - 12743983

AN - SCOPUS:0038755144

VL - 21

SP - 185

EP - 192

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 2

ER -